Novo Nordisk falls after Reuters report of Hims launching Wegovy pill copy

Shares of Danish drugmaker Novo Nordisk NOVOb.CO fall as Reuters reports that Hims and Hers Health HIMS.N is launching copies of Novo's Wegovy pill at an introductory price of $49 per month

Novo Nordisk's Denmark-listed shares down 10% at 274 Danish crowns; U.S. shares NVO.N fall 6.5% in premarket trading

Hims says its compounded pill uses the same active ingredient as Wegovy, semaglutide, and will cost $99 a month after an initial payment, compared with Novo's $199

Hims and Hers shares jump 13% before the bell

Novo last year ended a partnership with Hims and has raised safety and marketing concerns about compounded Wegovy copies

Earlier this week, Novo forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-loss market

Novo shares down ~42% in 2025